Biotest

Biotest EV/OCF

Delisted

The EV/OCF (Enterprise Value to Operating Cash Flow) of Biotest (BIO.DE) as of Nov 16, 2026 is 31.34. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -714.26 — a change of -104.39% (higher).

EV/OCF

31.34

YoY

-104.39%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Biotest is 2024 31.34 . EV/OCF (Enterprise Value to Operating Cash Flow) of Biotest was 2023 -714.26 . It decreases by -104.39% higher compared to the previous year.

The Biotest EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2017
50.60 EUR
Jan 1, 2018
-31.61 EUR
Jan 1, 2019
-50.04 EUR
Jan 1, 2020
-104.02 EUR
Jan 1, 2021
52.19 EUR
Jan 1, 2022
-46.04 EUR
Jan 1, 2023
-714.26 EUR
Jan 1, 2024
31.34 EUR
The Biotest EV/OCF history
YEAREV/OCFYoY
31.34-104.39%
-714.26+1,451.41%
-46.04-188.21%
52.19-150.18%
-104.02+107.90%
-50.04+58.28%
-31.61-162.48%
50.60+105.75%
24.59-39.48%
40.64-131.84%
-127.64—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biotest Stock analysis

What does Biotest do? Biotest AG is an innovative and successful company that operates in the fields of medicine, pharmacy, and biotechnology. It was founded in 1946 by Dr. Carl Adolf Vorherr in Dreieich near Frankfurt am Main. The company's original focus was on the development, production, and distribution of blood plasma products. In the 1950s, Biotest expanded into the field of transfusion medicine and began to clinically examine and process blood from donors. It became a leading manufacturer of concentrate preparations for the treatment of immune deficiencies and blood coagulation disorders in the 1960s. In the 1970s, the company became a leading manufacturer of monoclonal and polyclonal antibodies and an important research and development facility for biotechnological applications. Biotest today is divided into five research and business areas: Hematology & Immunology, Clinical Immunology, Biotherapeutics, Dermatology, and Research and Development. The company is globally present with locations in Europe, North America, Asia, and South America. It employs over 2,500 people and its products are available in more than 90 countries. It invests in research and development to stay at the forefront of technology and improve global health. Biotest is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biotest stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Biotest is 31.34 in 2024.

EV/OCF (Enterprise Value to Operating Cash Flow) of Biotest changed from -714.26 to 31.34, representing a -104.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Biotest since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Biotest with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biotest

All Key Metrics — Biotest